Specifying Contract Research Organization Services for a Prospective Observational Follow-Up of an Authorized Autologous Gene-Edited Cell Therapy: A Request-for-Proposal Framework
When a gene therapy has already shown substantial benefit and has been authorized, the scientifically honest next study is rarely another efficacy trial. This article builds a request for proposal (RFP) for a contract research organization (CRO) to run a 24-month, multicenter, prospective, non-interventional cohort study of adults with sickle cell disease previously treated, within routine authorized care, with a hypothetical autologous CRISPR/Cas9-edited hematopoietic stem cell therapy that raises fetal hemoglobin. The study neither procures nor administers the product. The article develops the evidence-to-RFP logic, specifies a 40-participant planning cohort at four to six United States centers, work packages, a 42-month timeline, a budget envelope of USD 1,805,500, a risk register, and weighted selection criteria, and addresses the regulatory classification, privacy, and safety-reporting questions that an observational gene therapy study raises. It emphasizes that a 24-month cohort cannot replace the long-term follow-up that regulators expect for genome-edited products.Keywords: request for proposal; gene editing; sickle cell disease; observational study; long-term follow-up; CRO; ICH E6(R3); real-world data
Authors
- Dorcas Koomson
- Peivand Pirouzi
- Gloria Anthonia Amoateng Agyemang
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425493
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00